Transthyretin amyloid cardiomyopathy
Estimates the relative prevalence of ATTR-CM by comparing clinical features extracted from the electronic health records of individual patients against a reference population
SA.001
Cardiology
General internal medicine
Canada
IL-1 mediated autoinflammatory diseases
Estimates the relative prevalence of adult-onset Still's disease and other IL-1 mediated autoinflammatory diseases by comparing clinical features extracted from the electronic health records of individual patients against a reference population
SA.004
Rheumatology
Canada
Amyotrophic lateral sclerosis
Estimates the relative prevalence of ALS by comparing clinical features extracted from the electronic health records of individual patients against a reference population
SA.006
Neurology
Canada
Paroxysmal nocturnal hemoglobinuria
Estimates the relative prevalence of PNH by comparing clinical features extracted from the electronic health records of individual patients against a reference population
SA.012
Gastroenterology
General internal medicine
Nephrology
Urology
Canada
Dyslipidemia
Identifies patients eligible for more intensive lipid management according to the 2021 Canadian Cardiovascular Society Dyslipidemia Guidelines
GA.001
Cardiology
General internal medicine
Canada
Cardiometabolic antidiabetic agents
Identifies patients eligible for medical management with a GLP-1 receptor agonist or SGLT2 inhibitor according to the Canadian Cardiovascular Society Guidelines for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults
GA.002
Cardiology
General internal medicine
Canada
Cardiometabolic antidiabetic agents
Identifies patients eligible for medical management with a GLP-1 receptor agonist or SGLT2 inhibitor according to the Diabetes Canada 2024 Clinical Practice Guidelines
GA.003
General internal medicine
Primary care
Canada
Heart failure
Identifies patients eligible for more intensive lipid management according to the 2021 Canadian Cardiovascular Society Dyslipidemia Guidelines
OA.006
Cardiology
General internal medicine
Canada
Cardiometabolic antidiabetic agents
Identifies patients eligible for medical management with a GLP-1 receptor agonist or SGLT2 inhibitor according to the Canadian Cardiovascular Society Guidelines for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults
GA.002
Rheumatology
Canada
Cardiometabolic antidiabetic agents
Identifies patients eligible for medical management with a GLP-1 receptor agonist or SGLT2 inhibitor according to the Diabetes Canada 2024 Clinical Practice Guidelines
GA.003
Cardiology
Endocrinology
General internal medicine
Primary care
Canada
Our algorithms rely exclusively on relevant clinical parameters. We don't employ big data techniques to draw loose inferences from codes or claims or require structured data. Our machine learning tools are embedded in our data extraction platform rather than in our algorithms. They only operate unsupervised at thresholds that yield 100% accuracy. We manage uncertainty with technology-enabled abstraction by trained healthcare professionals.
This allows us to build tools that are unrivalled in their precision. It's why our ATTR-CM algorithm is driven by reported echo parameters like IVSD, E/E' and GLS, why our ALS algorithm can incorporate the presence of sharp waves on EMG in patients with clinical fasciculations and why our IL-1 mediated autoinflammatory diseases algorithm can account for fever periodicity in its calculations.
Our reports clearly and transparently explain why patients may be suitable for follow-up investigations or referrals to specialty centres. The clinical parameters that drove our calculations are always reported alongside pertinent positives, pertinent negatives and other signs or symptoms necessary to complete the clinical picture.
Our mission is to empower physicians with better tools. Our reports reflect our best efforts to realize it.
We deploy our digital diagnostics exclusively at our clinical data labs because:
It allows us to control for variability in source data formats;
We can achieve greater reliability and accuracy than if we were to deploy our solutions locally; and
It makes life easier for our customers.
We go to great lengths to keep health information safe and secure including through the adoption of novel asymmetric de-identification and encryption techniques.